A Comprehensive Review of Dossier Submissions: Comparative Analysis of CTD and ATD Formats

1.1 Pharmaceutical Regulatory Submissions and Their Importance

Pharmaceutical regulatory submissions are a critical component of the drug development and commercialisation process [1]. Before a medicinal product can be marketed, regulatory authorities require comprehensive scientific evidence to ensure that the product consistently meets established standards of quality, safety, and efficacy [2]. These requirements are particularly stringent for generic products, where therapeutic performance must be demonstrated to be equivalent to that of a previously approved reference product. The primary mechanism through which this evidence is communicated to regulatory authorities is the pharmaceutical dossier. A well-structured dossier enables regulators to systematically evaluate manufacturing processes, control strategies, stability data, and clinical performance [1,3]. Conversely, deficiencies in dossier preparation often lead to regulatory queries, approval delays, or rejection [4]. As a result, dossier development has become a specialized discipline within regulatory affairs and pharmaceutical quality assurance [3].

1.2 Evolution of Global Dossier Formats

Historically, pharmaceutical dossier submissions were country-specific, requiring manufacturers to prepare entirely different documentation packages for each target market [5]. Quality testing must include compatibility assessments with intended packaging to prevent degradation during shelf life [6]. This lack of standardization resulted in duplication of effort, increased development costs, and delayed patient access to medicines [7,8]. To address these challenges, international harmonization initiatives were introduced, culminating in the development of the Common Technical Document (CTD) by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The CTD was designed to provide a unified structure for presenting quality, non-clinical, and clinical data across major regulatory markets [1]. Its adoption by ICH member regions significantly streamlined the submission and review process [8]. However, many emerging and developing markets adopted modified or region-specific versions of the CTD to suit local regulatory capacities and public health priorities. Within Southeast Asia, regulatory authorities under the Association of Southeast Asian Nations introduced the ASEAN Technical Dossier (ATD) to promote regional harmonization while retaining flexibility for national requirements [9]. Although conceptually aligned with the CTD, the ATD differs in organization, documentation depth, and regulatory interpretation [5,9]. These differences become increasingly significant when manufacturers attempt to adapt a single generic product dossier for multiple regulatory jurisdictions [5].

1.3 Regulatory Complexity in Generic Product Submissions

Generic pharmaceutical products are approved through abbreviated regulatory pathways that rely on the demonstration of pharmaceutical equivalence and bioequivalence rather than full clinical efficacy trials. Despite this abbreviated approach, regulatory expectations for quality documentation are often as rigorous as those applied to innovator products [2,3]. This is especially true for compounds with complex physicochemical properties, low solubility, extended elimination half-lives, or sensitivity to manufacturing variations [10]. Regulatory authorities closely scrutinise critical quality attributes such as impurity profiles, dissolution behaviour, stability under accelerated and long-term conditions, and consistency of manufacturing processes [2,3,11]. Differences in how these data are structured and presented between CTD and ATD formats frequently lead to regulatory challenges [5,9]. Manufacturers must not only generate scientifically robust data but also present it in a manner aligned with region-specific regulatory expectations [1,9].

1.4 Rationale for Comparative Evaluation of CTD and ATD Frameworks

Although both CTD and ATD frameworks aim to ensure the availability of safe and effective generic medicines, their practical implementation differs substantially [1,9]. The CTD emphasizes comprehensive documentation, standardized summaries (particularly Module 2), and electronic submission formats such as eCTD [1,12]. In contrast, the ATD allows greater flexibility in data presentation and level of detail, reflecting regional regulatory capacities [9]. While this flexibility may benefit emerging regulatory systems, it can also create ambiguity regarding data sufficiency and increase the likelihood of regulatory queries [5]. A critical evaluation of these frameworks is essential to identify harmonization gaps, recurring regulatory challenges, and opportunities for improving dossier preparation strategies [7,8]. Such evaluation is particularly relevant in postgraduate pharmaceutical education and regulatory practice, where cross-regional regulatory understanding is increasingly important [3].

2. Evolution Of Harmonized Dossier Formats

2.1 Development of CTD

The CTD format was finalized in 2000 under the ICH M4 guideline titled “Organisation of the Common Technical Document”. The objective was to harmonize technical documentation requirements across ICH regions and facilitate simultaneous submissions [1,7].

The CTD structure consists of five modules:

• Module 1: Regional Administrative Information
• Module 2: CTD Summaries
• Module 3: Quality (CMC)
• Module 4: Nonclinical Study Reports
• Module 5: Clinical Study Reports

Modules 2–5 are harmonized across regions, while Module 1 remains region-specific.

2.2 Development of ASEAN Technical Dossier (ATD)

The ASEAN Common Technical Dossier (ACTD) and ASEAN Common Technical Requirements (ACTR) were developed to standardize pharmaceutical registration among ASEAN member states. The ATD structure differs slightly from CTD but covers similar technical content [5,9]

The ATD consists of four parts:

• Part I: Administrative Data
• Part II: Quality Documentation
• Part III: Nonclinical Documentation
• Part IV: Clinical Documentation.

3. STRUCTURE AND CONTENT OF THE CTD FORMAT

3.1 Module 1 – Administrative Information

Module 1 includes region-specific administrative documents such as application forms, labeling, prescribing information, patent certification, and GMP certificates [1]. Although not harmonized, Module 1 is essential for regulatory processing.

3.2 Module 2 – CTD Summaries

Module 2 provides high-level summaries of quality, nonclinical, and clinical data.

It includes:

• Quality Overall Summary (QOS)
• Nonclinical Overview and Summary
• Clinical Overview and Summary

The purpose of Module 2 is to provide critical analysis and interpretation of detailed reports contained in Modules 3, 4, and 5.

3.3 Module 3 – Quality (CMC Documentation)

Module 3 is the most detailed section and provides comprehensive information on drug substance and drug product.

3.3.1 Drug Substance

• General information
• Manufacture
• Characterization
• Control of drug substance
• Reference standards
• Stability data

Pharmaceutical development principles described in ICH Q8 emphasize understanding of critical quality attributes and risk-based formulation development [2].

3.3.2 Drug Product

• Description and composition
• Pharmaceutical development
• Manufacturing process and controls
• Control of excipients
• Specifications
• Container closure system
• Stability studies

Risk management principles outlined in ICH Q9 are often integrated into Module 3 documentation [2,13].

3.4 Module 4 – Nonclinical Study Reports

Module 4 includes pharmacology, pharmacokinetics, and toxicology studies conducted according to Good Laboratory Practice (GLP) standards. Nonclinical data support initial human exposure and help determine safe starting doses for clinical trials.

3.5 Module 5 – Clinical Study Reports

Module 5 includes clinical pharmacology, biopharmaceutics, and clinical trial reports [1]. Clinical study reports must follow structured reporting principles to ensure transparency and reproducibility.

4. Structure and Content Of The Asean Technical Dossier (ATD)

4.1 Part I – Administrative Data

Part I includes application forms, product information, labeling, and authorization documents. Administrative requirements may vary slightly among ASEAN countries.

4.2 Part II – Quality Documentation

Part II corresponds broadly to CTD Module 3 and includes detailed CMC information.

Sections typically include:

• Drug substance information
• Drug product information
• Specifications
• Stability data

4.3 Part III – Nonclinical Documentation

Part III contains nonclinical pharmacology and toxicology information similar to CTD Module 4

4.4 Part IV – Clinical Documentation

Part IV includes bioequivalence studies, clinical trial reports, and literature references.

Bioequivalence requirements are generally aligned with international standards, though local variations may exist [5,9].

5. Electronic Dossier Submissions

The electronic Common Technical Document (eCTD) is a structured electronic submission format mandated in many regulatory regions including the US and EU

eCTD enhances lifecycle management, facilitates review efficiency, and supports regulatory transparency

ASEAN countries are progressively implementing electronic submission systems aligned with CTD principles [5,12,14]

6. Common Challenges in Dossier preparation

Common issues identified in regulatory submissions include:

• Incomplete stability data
• Insufficient process validation documentation
• Inadequate risk assessment justification
• Inconsistent specifications between sections

In ATD submissions, additional challenges may include country-specific labeling requirements and documentation translations.

7. Best Practices in Dossier Preparation

Effective strategies include:

1. Early regulatory planning
2. Gap analysis against CTD/ATD checklists
3. Cross-functional coordination between R&D and regulatory teams
4. Alignment with ICH quality guidelines
5. Proper lifecycle management for variations and renewals

FUTURE PERSPECTIVES

Regulatory convergence continues to expand beyond ICH regions. ASEAN harmonization initiatives aim to align further with global CTD standards. Increased reliance on digital platforms, risk-based assessment models, and real-world evidence is anticipated in future submissions.

CONCLUSION

The CTD and ASEAN Technical Dossier formats represent structured frameworks that facilitate systematic regulatory evaluation of pharmaceutical products. While CTD serves as the globally harmonized model, ATD provides regional alignment within ASEAN. Despite structural differences, both formats emphasize comprehensive documentation of quality, safety, and efficacy. Understanding the nuances of each format is essential for successful marketing authorization across multiple regions.

REFERENCES

1. ICH M4: Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use.
2. ICH Q8(R2): Pharmaceutical Development.
3. ICH. Q10: Pharmaceutical Quality System.
4. US Food and Drug Administration (USFDA). Refuse-to-Receive Standards for ANDAs. Guidance for Industry; 2016.
5. ASEAN Common Technical Requirements (ACTR).
6. Sayeed S, Goyal A. Eco- friendly biosurfactants in shampoo: Green chemistry innovations for sustainable personal care. J Dermatol Sci CosmetTechnol. 2025;2(3):100105
7. ICH Harmonisation History Documentation.
8. European Medicines Agency (EMA). The Common Technical Document: An Introduction.
9. ASEAN Common Technical Dossier (ACTD) Guidelines.
10. ICH. Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products.
11. ICH. Q1A(R2): Stability Testing of New Drug Substances and Products.
12. USFDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format – eCTD.
13. ICH Q9: Quality Risk Management.
14. EMA eCTD Specification and Guidance.